Ark Therapeutics, an Anglo-Finnish company announced that its was granted a permission to supply it's gene therapy drug Cerepro to named patients in Finland. Previously the company had obtained a similar approval for named patients in France after a submission by a local neurosurgeon.
Ark is expected to receive MAA decision from EMEA later this year and possibly become a first company to market gene therapy drugs in EU:
